Mark Bagnall
Founder at Naia Rare Diseases LLC
Profile
Mark N.
K.
Bagnall is the founder and the Chief Operating Officer of Naia Rare Diseases LLC, which was founded in 2014.
He is currently the Chief Executive Officer of Phenomix Sciences LLC since 2021, Chairman of XCR Diagnostics, Inc., and Director of Ativa Medical Corp.
since 2014.
Mr. Bagnall has previously held positions as Director at ThermoGenesis Holdings, Inc. in 2016, Director at Forticell Bioscience, Inc. from 2007 to 2008, Independent Director at VIA Pharmaceuticals, Inc. from 2007 to 2011, President & Director at GENTURAdx USA, Inc. in 2011, Principal at Somatix Therapy Corp., Principal at Progenitor, Inc., Chief Financial Officer & Executive Vice President at Mast Therapeutics, Inc. in 2009, SVP, Chief Operating & Financial Officer at CymaBay Therapeutics, Inc. from 2000 to 2007, and Principal at Metrika, Inc. Mr. Bagnall completed his undergraduate degree at the University of California, Berkeley.
Mark Bagnall active positions
| Companies | Position | Start |
|---|---|---|
Ativa Medical Corp.
 Ativa Medical Corp. Medical SpecialtiesHealth Technology Ativa Medical Corp. provides medical diagnostic solutions. It offers analyzers that perform critical hematology and clinical chemistry tests; and disposable test cards for trauma, pediatric, oncology and geriatric patients. The company was founded by David W. Deetz in 2008 and is headquartered in St. Paul, MN. | Director/Board Member | 2014-11-18 |
Naia Rare Diseases LLC
 Naia Rare Diseases LLC Medical/Nursing ServicesHealth Services Naia Rare Diseases, Inc. develops pharmaceutical drugs for Short Bowel Syndrome (SBS) and other rare gastrointestinal diseases. The firm offers NB 1001 for adult SBS, NB 1001 for pediatric SBS, and NB 1002, a GLP-2 agonist. The company was founded by H. Daniel Perez and Mark Bagnall in 2014 and is headquartered in Cayman Islands. | Founder | 2013-12-31 |
XCR Diagnostics, Inc.
 XCR Diagnostics, Inc. Medical SpecialtiesHealth Technology XCR Diagnostics, Inc. develops and delivers molecular diagnostic systems. The firm offers assays in development, portable nucleic acid testing, and sample delivery system services. The company was founded in April 2015 and is headquartered in Salt Lake City, UT. | Chairman | - |
Phenomix Sciences LLC
 Phenomix Sciences LLC Medical/Nursing ServicesHealth Services Phenomix Sciences LLC engages in the provision of healthcare solutions to enable personalized management of chronic diseases. The company was founded by Andres Acosta and Michael Camilleri in 2017 and is headquartered in St. Paul, MN. | Chief Executive Officer | 2021-01-31 |
Former positions of Mark Bagnall
| Companies | Position | End |
|---|---|---|
| THERMOGENESIS HOLDINGS, INC. | Director/Board Member | 2016-11-02 |
| VIA PHARMACEUTICALS, INC. | Director/Board Member | 2010-12-31 |
Mast Therapeutics, Inc.
 Mast Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Mast Therapeutics, Inc. is a biopharmaceutical company, which engages in developing novel therapies for serious or life-threatening diseases with significant unmet needs. It leveraging Molecular Adhesion and Sealant Technology, platform, derived from over two decades of clinical, nonclinical, and manufacturing experience with purified and non-purified poloxamers to develop vepoloxamer, which also known as MST-188. The company was founded by Warren C. Lau in December 1995 and is headquartered in San Diego, CA. | Director of Finance/CFO | 2009-08-23 |
Forticell Bioscience, Inc.
 Forticell Bioscience, Inc. BiotechnologyHealth Technology Forticell Bioscience, Inc. focuses on advanced regenerative medicine and stem cell therapy. The company was founded in 1991 and is headquartered in Englewood Cliffs, NJ. | Director/Board Member | 2008-11-18 |
| CYMABAY THERAPEUTICS, INC. | Director of Finance/CFO | 2007-05-31 |
Training of Mark Bagnall
| University of California, Berkeley | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 2 |
|---|---|
| THERMOGENESIS HOLDINGS, INC. | Health Technology |
| VIA PHARMACEUTICALS, INC. | Health Technology |
| Private companies | 11 |
|---|---|
Somatix Therapy Corp.
 Somatix Therapy Corp. BiotechnologyHealth Technology Somatix Therapy Corp. researches, develops, and commercialize proprietary processes for the genetic modification of cells and their use in the treatment of human disease. Somatix's assets include its highly efficient gene transfer technology, broad-based intellectual property, and focused product development programs. The company's most advanced clinical development program, the GVAX cancer vaccine, is in Phase I/II clinical trials for the treatment of metastatic renal cell carcinoma, advanced melanoma, and prostate cancer. It is located in Alameda, CA | Health Technology |
Forticell Bioscience, Inc.
Forticell Bioscience, Inc. BiotechnologyHealth Technology Forticell Bioscience, Inc. focuses on advanced regenerative medicine and stem cell therapy. The company was founded in 1991 and is headquartered in Englewood Cliffs, NJ. | Health Technology |
Progenitor, Inc.
 Progenitor, Inc. BiotechnologyHealth Technology Progenitor, Inc. is an American private company. The firm develops pharmaceutical compounds for nervous system. The company is headquartered in Columbus, OH. | Health Technology |
Mast Therapeutics, Inc.
Mast Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Mast Therapeutics, Inc. is a biopharmaceutical company, which engages in developing novel therapies for serious or life-threatening diseases with significant unmet needs. It leveraging Molecular Adhesion and Sealant Technology, platform, derived from over two decades of clinical, nonclinical, and manufacturing experience with purified and non-purified poloxamers to develop vepoloxamer, which also known as MST-188. The company was founded by Warren C. Lau in December 1995 and is headquartered in San Diego, CA. | Health Technology |
CymaBay Therapeutics, Inc.
 CymaBay Therapeutics, Inc. BiotechnologyHealth Technology CymaBay Therapeutics, Inc. engages in the provision and development of access to therapies for patients with liver and other chronic diseases with high unmet medical needs. Its products pipeline includes Seladelpar, MBX-2982, CB-0406, and CB-001. The company was founded on October 5, 1988 and is headquartered in Newark, CA. | Health Technology |
Metrika, Inc.
 Metrika, Inc. BiotechnologyHealth Technology Metrika Inc. manufactures and markets disease-monitoring products. It also manufactures other chronic condition products. The company was founded in 1994 by Michael P. Allen and is headquartered in Sunnyvale, CA. | Health Technology |
GENTURAdx USA, Inc.
 GENTURAdx USA, Inc. Medical SpecialtiesHealth Technology GENTURAdx USA, Inc. manufactured biotechnology instruments. The firm provided tools necessary for detection and treatment of diseases and drug discoveries. It had offices in the Silicon Valley, Hong Kong, Shanghai and Suzhou. The company was founded by Steve Yu and Jesus Ching in June 2005 and was headquartered in Hayward, CA. | Health Technology |
Ativa Medical Corp.
Ativa Medical Corp. Medical SpecialtiesHealth Technology Ativa Medical Corp. provides medical diagnostic solutions. It offers analyzers that perform critical hematology and clinical chemistry tests; and disposable test cards for trauma, pediatric, oncology and geriatric patients. The company was founded by David W. Deetz in 2008 and is headquartered in St. Paul, MN. | Health Technology |
XCR Diagnostics, Inc.
XCR Diagnostics, Inc. Medical SpecialtiesHealth Technology XCR Diagnostics, Inc. develops and delivers molecular diagnostic systems. The firm offers assays in development, portable nucleic acid testing, and sample delivery system services. The company was founded in April 2015 and is headquartered in Salt Lake City, UT. | Health Technology |
Phenomix Sciences LLC
Phenomix Sciences LLC Medical/Nursing ServicesHealth Services Phenomix Sciences LLC engages in the provision of healthcare solutions to enable personalized management of chronic diseases. The company was founded by Andres Acosta and Michael Camilleri in 2017 and is headquartered in St. Paul, MN. | Health Services |
Naia Rare Diseases LLC
Naia Rare Diseases LLC Medical/Nursing ServicesHealth Services Naia Rare Diseases, Inc. develops pharmaceutical drugs for Short Bowel Syndrome (SBS) and other rare gastrointestinal diseases. The firm offers NB 1001 for adult SBS, NB 1001 for pediatric SBS, and NB 1002, a GLP-2 agonist. The company was founded by H. Daniel Perez and Mark Bagnall in 2014 and is headquartered in Cayman Islands. | Health Services |
- Stock Market
- Insiders
- Mark Bagnall
